Clinical Trial: Chinese Liver Cancer Clinical Survey

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Observational

Official Title: Chinese Liver Cancer Clinical Survey

Brief Summary: In order to make better use of clinical resources of the real world, strengthen the standardization of PLC diagnosis and treatment, and constantly improve the academic level of liver cancer in China, we intends to launch "Chinese Liver Cancer clinical Survey" project in cancer specialized hospitals and large general hospitals and to explore the best clinical pathway of PLC multidisciplinary consultation.

Detailed Summary: Primary liver cancer (PLC) is one of the most common malignant tumors of digestive system and also a serious threat to the health and safety of Chinese people, and has caused serious economic burden to the country. Research purposes: To understand the clinical characteristics of patients with primary liver cancer (PLC) in China; To investigate the etiology and pathogenesis of PLC in China; To understand the current status of clinical treatment of PLC in China, and to analyze the gaps among these conditions and domestic treatment guidelines, industry consensus, the international treatment guidelines; To understand the different treatment options and its clinical outcomes, and to explore the best treatment options; To explore the best clinical pathway of PLC multidisciplinary consultation; To provide the basis for the development of clinical guidelines for PLC in China.
Sponsor: Beijing Insight Science & Technology Co. Ltd.

Current Primary Outcome: Overall survival [ Time Frame: 5 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Beijing Insight Science & Technology Co. Ltd.

Dates:
Date Received: May 19, 2017
Date Started: November 28, 2016
Date Completion: August 31, 2017
Last Updated: May 19, 2017
Last Verified: May 2017